SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?


To: ewolf who wrote (350)1/25/2003 12:02:00 PM
From: Michael Young  Read Replies (2) | Respond to of 508
 
Interesting.

Frankly, I doubt pirfenidone will work any better than actimmune. That Japanese Phase II study seems flaky, with a lot of supposed "trends" efficacy in a tiny trial.

The actimmune extension data suggest the drug provides minimal, at best, help against IPF.

MIKE